The notable increase in the IGFBP-3 level was detected in patients with osteosarcoma (4.39 ± 0.25), Ewing sarcoma (3.75 ± 0.12) and GCT (2.53 ± 0.15) compared to healthy controls (1.63 ± 0.08) (P < 0.0001); also the difference between patients with osteosarcoma compared to Ewing sarcoma (P=0.003) and GCT (P < 0.0001); and/also Ewing sarcoma and GCT (P < 0.0001) was remarkable (Figure 6B). Here, IGFBP3 is linked to Ewing sarcoma.